Replies to post #159660 on Biotech Values

[poorgradstudent]

ONXX:

Yes, but only marginally; however, many investors probably think the breakthrough therapy designation is a very big deal.

I agree. I was commenting more so from the market perception side.

I think the palbociclib data to date have been strong enough that breakthrough therapy designation is not altogether meaningful.

As a goofy aside, I think palbociclib is going to be an oft-misspelled name among investors. The allure of pablociclib is too high :-)